{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:50:26Z","timestamp":1792601426301,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52173281"],"award-info":[{"award-number":["52173281"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07287-w","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:42:24Z","timestamp":1751384544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Xianyu","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchuan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"7287_CR1","doi-asserted-by":"publisher","first-page":"1020058","DOI":"10.3389\/fonc.2022.1020058","volume":"12","author":"R Stoff","year":"2022","unstructured":"Stoff, R. et al. Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients. Front. Oncol. 12, 1020058. https:\/\/doi.org\/10.3389\/fonc.2022.1020058 (2022).","journal-title":"Front. Oncol."},{"key":"7287_CR2","doi-asserted-by":"publisher","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","volume":"5","author":"L Albiges","year":"2020","unstructured":"Albiges, L. et al. Nivolumab plus ipilimumab versus Sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III checkmate 214 trial. ESMO Open. 5, e001079. https:\/\/doi.org\/10.1136\/esmoopen-2020-001079 (2020).","journal-title":"ESMO Open."},{"key":"7287_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fonc.2020.00091","volume":"10","author":"AR Almutairi","year":"2020","unstructured":"Almutairi, A. R., McBride, A., Slack, M., Erstad, B. L. & Abraham, I. Potential Immune-Related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: A systematic review and Meta-Analysis. Front. Oncol. 10, 91. https:\/\/doi.org\/10.3389\/fonc.2020.00091 (2020).","journal-title":"Front. Oncol."},{"key":"7287_CR4","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1158\/1078-0432.Ccr-15-2944","volume":"22","author":"MS Carlino","year":"2016","unstructured":"Carlino, M. S. & Long, G. V. Ipilimumab combined with nivolumab: A standard of care for the treatment of advanced melanoma?? Clin. Cancer Res. 22, 3992\u20133998. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2944 (2016).","journal-title":"Clin. Cancer Res."},{"key":"7287_CR5","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced Non-Small-Cell lung Cancer. N Engl. J. Med. 381, 2020\u20132031. https:\/\/doi.org\/10.1056\/NEJMoa1910231 (2019).","journal-title":"N Engl. J. Med."},{"key":"7287_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki, Y. et al. Nivolumab combination therapy in advanced esophageal Squamous-Cell carcinoma. N Engl. J. Med. 386, 449\u2013462. https:\/\/doi.org\/10.1056\/NEJMoa2111380 (2022).","journal-title":"N Engl. J. Med."},{"key":"7287_CR7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters, S. et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from checkmate 743. Ann. Oncol. 33, 488\u2013499. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.074 (2022).","journal-title":"Ann. Oncol."},{"key":"7287_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamaoncol.2023.0147","volume":"9","author":"KJ Harrington","year":"2023","unstructured":"Harrington, K. J. et al. Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 checkmate 714 randomized clinical trial. JAMA Oncol. 9, 779\u2013789. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0147 (2023).","journal-title":"JAMA Oncol."},{"key":"7287_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1186\/s12885-024-12336-0","volume":"24","author":"JC Janssen","year":"2024","unstructured":"Janssen, J. C. et al. Safe stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol. BMC Cancer. 24, 632. https:\/\/doi.org\/10.1186\/s12885-024-12336-0 (2024).","journal-title":"BMC Cancer"},{"key":"7287_CR10","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/s1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi, F. S. et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 19, 1480\u20131492. https:\/\/doi.org\/10.1016\/s1470-2045(18)30700-9 (2018).","journal-title":"Lancet Oncol."},{"key":"7287_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok, J. D. et al. Long-Term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127\u2013137. https:\/\/doi.org\/10.1200\/JCO.21.02229 (2022).","journal-title":"J. Clin. Oncol."},{"key":"7287_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s40425-019-0743-5","volume":"7","author":"J Yang","year":"2019","unstructured":"Yang, J., Lagana, S. M., Saenger, Y. M. & Carvajal, R. D. Dual checkpoint inhibitor-associated eosinophilic enteritis. J. Immunother Cancer. 7, 310. https:\/\/doi.org\/10.1186\/s40425-019-0743-5 (2019).","journal-title":"J. Immunother Cancer"},{"key":"7287_CR13","doi-asserted-by":"publisher","unstructured":"Sakai, K. et al. A Case of nivolumab-induced severe mononeuropathy multiplex and rhabdomyolysis. Case Rep. Med. 1093858, (2017). https:\/\/doi.org\/10.1155\/2017\/1093858 (2017).","DOI":"10.1155\/2017\/1093858"},{"key":"7287_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1248\/bpb.35.967","volume":"35","author":"K Kadoyama","year":"2012","unstructured":"Kadoyama, K., Sakaeda, T., Tamon, A. & Okuno, Y. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and drug administration adverse event reporting system. Biol. Pharm. Bull. 35, 967\u2013970. https:\/\/doi.org\/10.1248\/bpb.35.967 (2012).","journal-title":"Biol. Pharm. Bull."},{"key":"7287_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement. Drug Saf. 47, 575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9 (2024).","journal-title":"Drug Saf."},{"key":"7287_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","volume":"44","author":"A Mascolo","year":"2021","unstructured":"Mascolo, A. et al. Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance. Drug Saf. 44, 957\u2013971. https:\/\/doi.org\/10.1007\/s40264-021-01086-8 (2021).","journal-title":"Drug Saf."},{"key":"7287_CR17","doi-asserted-by":"publisher","unstructured":"Wang, J., Zhang, A., Ye, M. & Zhang, C. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database. Front. Pharmacol. 15 https:\/\/doi.org\/10.3389\/fphar.2024.1376535 (2024).","DOI":"10.3389\/fphar.2024.1376535"},{"key":"7287_CR18","doi-asserted-by":"publisher","first-page":"e0278725","DOI":"10.1371\/journal.pone.0278725","volume":"17","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for venetoclax. PLoS One. 17, e0278725. https:\/\/doi.org\/10.1371\/journal.pone.0278725 (2022).","journal-title":"PLoS One"},{"key":"7287_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","volume":"45","author":"S Kinoshita","year":"2020","unstructured":"Kinoshita, S., Hosomi, K., Yokoyama, S. & Takada, M. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J. Clin. Pharm. Ther. 45, 65\u201371. https:\/\/doi.org\/10.1111\/jcpt.13024 (2020).","journal-title":"J. Clin. Pharm. Ther."},{"key":"7287_CR20","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jamadermatol.2020.0470","volume":"156","author":"CM Olsen","year":"2020","unstructured":"Olsen, C. M., Thompson, J. F., Pandeya, N. & Whiteman, D. C. Evaluation of sex-specific incidence of melanoma. JAMA Dermatol.  156, 553\u2013560 (2020).","journal-title":"JAMA Dermatology"},{"key":"7287_CR21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","volume":"198","author":"M Alexander","year":"2020","unstructured":"Alexander, M., Kim, S. Y. & Cheng, H. Update 2020: management of Non-Small cell lung Cancer. Lung 198, 897\u2013907. https:\/\/doi.org\/10.1007\/s00408-020-00407-5 (2020).","journal-title":"Lung"},{"key":"7287_CR22","doi-asserted-by":"publisher","first-page":"g4797","DOI":"10.1136\/bmj.g4797","volume":"349","author":"E Jonasch","year":"2014","unstructured":"Jonasch, E., Gao, J. & Rathmell, W. K. Renal cell carcinoma. Bmj 349, g4797. https:\/\/doi.org\/10.1136\/bmj.g4797 (2014).","journal-title":"Bmj"},{"key":"7287_CR23","unstructured":"National Academies of Sciences, E. & Medicine Diagnosing and Treating Adult Cancers and Associated Impairments (National Academies, 2021)."},{"key":"7287_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Longo, D. L., Sidlow, R. & Hellmann, M. D. Immune-Related adverse events associated with immune checkpoint Blockade. N. Engl. J. Med. 378, 158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481 (2018).","journal-title":"N. Engl. J. Med."},{"key":"7287_CR25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/er.2004-0011","volume":"26","author":"P Caturegli","year":"2005","unstructured":"Caturegli, P. et al. Autoimmune hypophysitis. Endocr. Rev. 26, 599\u2013614. https:\/\/doi.org\/10.1210\/er.2004-0011 (2005).","journal-title":"Endocr. Rev."},{"key":"7287_CR26","doi-asserted-by":"publisher","unstructured":"Barroso-Sousa, R. et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens. JAMA Oncol. 4 https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064 (2018).","DOI":"10.1001\/jamaoncol.2017.3064"},{"key":"7287_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"Chang, L. S. et al. Endocrine toxicity of Cancer immunotherapy targeting immune checkpoints. Endocr. Rev. 40, 17\u201365. https:\/\/doi.org\/10.1210\/er.2018-00006 (2019).","journal-title":"Endocr. Rev."},{"key":"7287_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/coc.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder, E. I. & Desai, A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their Inhibition. Am. J. Clin. Oncol. 39, 98\u2013106. https:\/\/doi.org\/10.1097\/coc.0000000000000239 (2016).","journal-title":"Am. J. Clin. Oncol."},{"key":"7287_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","volume":"58","author":"M Sznol","year":"2017","unstructured":"Sznol, M. et al. Endocrine-related adverse events associated with immune checkpoint Blockade and expert insights on their management. Cancer Treat. Rev. 58, 70\u201376. https:\/\/doi.org\/10.1016\/j.ctrv.2017.06.002 (2017).","journal-title":"Cancer Treat. Rev."},{"key":"7287_CR30","doi-asserted-by":"publisher","unstructured":"Yonezaki, K. et al. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with hashimoto\u2019s disease and diabetes mellitus: a case report. J. Med. Case Rep. 12 https:\/\/doi.org\/10.1186\/s13256-018-1708-x (2018).","DOI":"10.1186\/s13256-018-1708-x"},{"key":"7287_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3345\/kjp.2013.56.12.519","volume":"56","author":"SJ Park","year":"2013","unstructured":"Park, S. J. & Shin, J. I. Inflammation and hyponatremia: an underrecognized condition? Korean J. Pediatr. 56, 519\u2013522. https:\/\/doi.org\/10.3345\/kjp.2013.56.12.519 (2013).","journal-title":"Korean J. Pediatr."},{"key":"7287_CR32","doi-asserted-by":"publisher","unstructured":"Mamlouk, O. et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J. Immunother Cancer. 7 https:\/\/doi.org\/10.1186\/s40425-018-0478-8 (2019).","DOI":"10.1186\/s40425-018-0478-8"},{"key":"7287_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3949\/ccjm.90a.22032","volume":"90","author":"R Kennedy","year":"2023","unstructured":"Kennedy, R., Awada, H., Vura, N., Ciltea, D. & Morocco, M. Endocrinopathies from checkpoint inhibitors: incidence, outcomes, and management. Cleve Clin. J. Med. 90, 307\u2013317. https:\/\/doi.org\/10.3949\/ccjm.90a.22032 (2023).","journal-title":"Cleve Clin. J. Med."},{"key":"7287_CR34","doi-asserted-by":"publisher","unstructured":"Abu-Sbeih, H. et al. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J. Immunother. Cancer. 7 https:\/\/doi.org\/10.1186\/s40425-019-0604-2 (2019).","DOI":"10.1186\/s40425-019-0604-2"},{"key":"7287_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","volume":"67","author":"J Kashima","year":"2017","unstructured":"Kashima, J., Okuma, Y., Shimizuguchi, R. & Chiba, K. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol. Immunother. 67, 61\u201365. https:\/\/doi.org\/10.1007\/s00262-017-2062-3 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"7287_CR36","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1097\/meg.0000000000002280","volume":"33","author":"B Pi","year":"2021","unstructured":"Pi, B. et al. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. Eur. J. Gastroenterol. Hepatol. 33, e858\u2013e867. https:\/\/doi.org\/10.1097\/meg.0000000000002280 (2021).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"7287_CR37","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.ophtha.2019.01.031","volume":"126","author":"JM Kim","year":"2019","unstructured":"Kim, J. M. et al. Ophthalmic Immune-Related adverse events of immunotherapy: A Single-Site case series. Ophthalmology 126, 1058\u20131062. https:\/\/doi.org\/10.1016\/j.ophtha.2019.01.031 (2019).","journal-title":"Ophthalmology"},{"key":"7287_CR38","first-page":"123","volume":"2","author":"DH Let\u00edcia Quinane","year":"2020","unstructured":"Let\u00edcia Quinane, D. H., Ladislau, L. & Tarouquella, C. C. J. Autoimmune cystitis: an unusual adverse effect of the ipilimumab\/nivolumab combination in metastatic renal cell Carcinoma\u2013Case report and review of literature. Int. J. Clin. Case Stud. Rep. 2, 123\u2013127 (2020).","journal-title":"Int. J. Clin. Case Stud. Rep."},{"key":"7287_CR39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.36401\/jipo-23-44","volume":"7","author":"K Jazieh","year":"2024","unstructured":"Jazieh, K., Kottschade, L. & Dimou, A. Keeping an eye out for immunotherapy toxicity: A case of unilateral ptosis caused by ipilimumab\/nivolumab therapy. J. Immunother Precis Oncol. 7, 126\u2013129. https:\/\/doi.org\/10.36401\/jipo-23-44 (2024).","journal-title":"J. Immunother Precis Oncol."},{"key":"7287_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/cji.0000000000000184","volume":"41","author":"JM Zecchini","year":"2018","unstructured":"Zecchini, J. M., Kim, S., Yum, K. & Friedlander, P. Development of bell\u2019s palsy after treatment with ipilimumab and nivolumab for metastatic melanoma: A case report. J. Immunother. 41, 39\u201341. https:\/\/doi.org\/10.1097\/cji.0000000000000184 (2018).","journal-title":"J. Immunother"},{"key":"7287_CR41","doi-asserted-by":"publisher","first-page":"ii175","DOI":"10.1093\/eurheartjsupp\/suae036.425","volume":"26","author":"A Logiacco","year":"2024","unstructured":"Logiacco, A. et al. A rare case of Ipilimumab\/Nivolumab\u2013Induced myocarditis complicated by high grade atrioventricular block in a patient with metastatic renal cell Cancer. Eur. Heart J. Supplements. 26, ii175\u2013ii175. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suae036.425 (2024).","journal-title":"Eur. Heart J. Supplements"},{"key":"7287_CR42","doi-asserted-by":"publisher","first-page":"e36446","DOI":"10.7759\/cureus.36446","volume":"15","author":"H Kondo","year":"2023","unstructured":"Kondo, H., Kirigaya, J., Matsuzawa, Y. & Hibi, K. Two cases of immune checkpoint Inhibitor-Induced myocarditis with complete atrioventricular block. Cureus 15, e36446. https:\/\/doi.org\/10.7759\/cureus.36446 (2023).","journal-title":"Cureus"},{"key":"7287_CR43","doi-asserted-by":"publisher","unstructured":"Stadler, K., Liu, S., Navarro, G. & Mauvais-Jarvis, F. Androgen excess produces systemic oxidative stress and predisposes to \u03b2-Cell failure in female mice. PLoS One. 5 https:\/\/doi.org\/10.1371\/journal.pone.0011302 (2010).","DOI":"10.1371\/journal.pone.0011302"},{"key":"7287_CR44","doi-asserted-by":"publisher","unstructured":"Patel, K. H. K. et al. Obesity as a risk factor for cardiac arrhythmias. BMJ Med. 1 https:\/\/doi.org\/10.1136\/bmjmed-2022-000308 (2022).","DOI":"10.1136\/bmjmed-2022-000308"},{"key":"7287_CR45","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","volume":"15","author":"NE Ready","year":"2020","unstructured":"Ready, N. E. et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the checkmate 032 randomized cohort. J. Thorac. Oncol. 15, 426\u2013435. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.004 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"7287_CR46","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1200\/jco.19.00538","volume":"37","author":"P Sharma","year":"2019","unstructured":"Sharma, P. et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: checkmate 032 nivolumab 1\u00a0mg\/kg plus ipilimumab 3\u00a0mg\/kg expansion cohort results. J. Clin. Oncol. 37, 1608\u20131616. https:\/\/doi.org\/10.1200\/jco.19.00538 (2019).","journal-title":"J. Clin. Oncol."},{"key":"7287_CR47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma, P. et al. Nivolumab plus ipilimumab for metastatic Castration-Resistant prostate cancer: preliminary analysis of patients in the checkmate 650 trial. Cancer Cell. 38, 489\u2013499e483. https:\/\/doi.org\/10.1016\/j.ccell.2020.08.007 (2020).","journal-title":"Cancer Cell."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07287-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07287-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07287-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:42:26Z","timestamp":1751384546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07287-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7287"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07287-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21055"}}